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At the end of 2019, the world encountered a devastating disease caused by a corona virus SARS-CoV-2 and
named after it COVID-19. Its high morbidity and mortality resulted in a worldwide healthcare emergency, which in
turn accelerated and amplified efforts in the relevant areas of health sciences research and practice.
The entire genome of SARS-CoV-2 was sequenced and made public on GISAID (accession ID:
EPI_ISL_402119; EPI_ISL_402120; EPI_ISL_402121)1. When compared to the genomes of other viruses, the SARSCoV-2 genome has 79.5% nucleotide similarity with SARS-CoV, which appeared in Guangdong Province in China
in 2002, about 50% similarity with MERS-CoV, which emerged in the Middle Eastern countries in 2012, and 96%
similarity with the bat coronavirus CoV RaTG131.
Reaching herd immunity by achieving a 70-80% vaccination rate became a primary strategy to tackle the
pandemia. Just in about a year from virus identification, on December 11, 2020, Pfizer-BioNTech COVID-19 Vaccine
became available in the USA under the Food and Drug Administration (FDA) Emergency Use Authorization. Since
then multiple COVID-19 vaccines have mushroomed around the world including Oxford–AstraZeneca (Vaxzevria,
Covishield), Pfizer–BioNTech (Comirnaty), Moderna (Spikevax), Janssen (Johnson & Johnson COVID-19 vaccine),
Sinopharm (BBIBP-CorV), Gamaleya Research Institute of Epidemiology and Microbiology ( Sputnik V), Bharat
Biotech International Limited (Covaxin) and more than 20 others in various stages of development and approval.
However, management of COVID-19 disease remains complex, and thus it is a rapidly developing field of research
and clinical implementation.
The human body hosts an innumerable variety of viruses, described as the ‘virome’. It is estimated at
approximately 1013 particles per individual, with great heterogeneity2. A recent evolutionary analyses of human
genomic datasets unveiled that a strong genetic adaptation going 25,000 years back exists in East Asian human
populations, where multiple genes interact with coronaviruses, including SARS-CoV-2 that started 25,000 years ago3.
Medicinal plants have been used for the treatment and mitigation of viral diseases long before 1796, when
Edward Jenner demonstrated that the “vaccinia” virus could protect against smallpox, and even before variolation was
used in China and India more than two millennia ago. For hundreds of years, the Native Americans who were severely
affected by smallpox, used poultices and infusions derived from Sarracenia purpurea to treat the disease. The antiviral
properties of this plant were confirmed in the modern experiments4.
During the desperate times of the Spanish Flu pandemic, people used herbal remedies such as Allium cepa,
Gelsemium sempervirens, Eupatorium perfoliatum, Actaea racemosa and Asclepias tuberosa to alleviate disease
burden. Oseltamivir (Tamiflu®), a drug derived from Illicium verum is FDA approved for the treatment of acute,
uncomplicated influenza in patients two weeks of age and older who have been symptomatic for no more than 2 days.
It is also available for prophylaxis of influenza in patients 1 year and older5.
The key steps in virus replication cycle are well researched6. The findings prompted the identification of
targets for the novel compunds and fine-tuning of the existing botanical entities. Those targets may include the phases
of SARS-CoV-2 entry, RNA replication, synthesis of polymerases, proteases, nonstructural and structural proteins, as
well as adaptive immune responses to SARS-CoV-2 infection. Plants contain millions of natural compounds, however
traditional screening for the compounds effective against SARS-CoV-2 is a very lengthy and labor-consuming
process. A recently developed computational prediction process can be utilized as a rapid and efficient technique that
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engages the interaction between the plant in question and the spike (S) and the nucleocapsid (N) proteins of SARSCoV-2.
Obstructing the attachment of S protein to angiotensin converting enzyme 2 (ACE2) receptors is an attractive
and promising therapeutic modality in the management of COVID-19. The feasibility of such a blockade can be
accomplished by a number of compounds derived from the plants; as for example, it was shown for licoflavonol from
Glycyrrhiza uralensis, emodin from the genus Rheum and Polygonum, baicalin from Scutellariabaicalensis,
scutellarin from Erigeron breviscapus, 1,3,4,6-tetra-O-galloyl-β-D-glucose from Galla chinensis, luteolin from
Veronicalinariifolia.
Coronaviral non structural proteins, such as RNA-dependent RNA Polymerase (RdRp), is a critical enzyme
involved in the virus's RNA replication, transcription and protein translation, as well as in the modification and
processing of proteins. RdRp has been used as an important target to develop drugs against SARS, MERS and SAR
CoV-2. Some medicinal plants have demonstrated pharmacological activity by binding to RdRp. Another enzyme
responsible RNA replication and maturation of the viral polyproteins is 3-chymotrypsin like protease (3CLPro).
Betulonal (Cassinexylocarpa), gnidicin and gniditrin (Gnidialamprantha) bind to and inhibit the RdRpof
coronaviruses. Betulonal has been shown to inhibit both the RdRp and 3CLPro.
Neuraminidase is an essential enzyme required for viral spread across the host cells. Oseltamivir, as a
neuraminidase inhibitor blocks the release of viruses from the infected cells, thus shortening the disease duration.
Anti-inflammatory and immunomodulatory compounds work by inhibiting the pathological inflammatory
response induced by SARS-CoV-2 and other viruses. Their effects impede the pathogenesis by decreasing cytokine
production, specifically the release of IL6, IL1β and TNFα, and hindering cellular autophagy in the infected cells.
Blocking the interleukin signaling pathway may control the release of cytokines caused by SARS-CoV-2 infection.
Many flavonoids inhibit inflammatory cytokines thus exerting immunomodulatory and anti-inflammatory effects. For
example, liquiritin, a flavonoid extracted from the roots of Glycyrrhiza uralensis acts similarly to interferons hence
eliciting such a response.
Botanical therapeutics possess a unique potential in the treatment of viral diseases. The pharmacological base
and clinical use of botanical therapeutics have been extensively reviewed7-8. The mode of action(s) may be built either
on the direct interference with the virus ability to enter human cells, virus replication, or exerting immune-modulatory
and anti-inflammatory effects. The adjuvant treatment with botanical therapeutics has the potential to result in
advances in symptom resolution, decrease in disease burden and shortening its duration.
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